Danaher Corporation (DHR)

Over the past six months, Danaher's stock has experienced some notable movements. As of May 8, 2026, the stock was down 12.76% over the past 30 days and down 12.14% for the past 12 months. In April 2026, Danaher reported Q1 2026 adjusted EPS of $2.06, surpassing the consensus estimate of $1.94, but revenue for Q1 came in at $5.95 billion, slightly below the $6 billion consensus. Several large firms, including Goldman Sachs and Wolfe Research, reduced their price targets for DHR, though the consensus remained a "Moderate Buy."

Demand for Danaher's products and services can be influenced by seasonality and cyclicality, particularly in certain businesses. The company's molecular diagnostics unit, Cepheid, can experience headwinds from a lighter-than-typical respiratory season. Danaher's focus on non-discretionary healthcare markets, with approximately 80% of sales from consumables and services, provides a stable revenue base.

Danaher Corporation is an American healthcare company focused on biotechnology, life sciences, and diagnostics. It designs, manufactures, and markets professional, medical, research, and industrial products and services globally, structured around biotechnology (28% of 2024 revenues), life sciences (31% of 2024 revenues), and diagnostics (41% of 2024 revenues). Its offerings include technologies, consumables, and solutions for therapeutics development and manufacturing; instruments and consumables for disease identification, therapy development, and drug testing; and instruments, consumables, software, and services for disease diagnosis.

Danaher Corporation has a significant global presence, operating in 50 countries and 700 locations. It serves customers internationally, including the United States, China, Europe, Asia, and Australia. Approximately 38% of its revenue comes from the United States, 30% from Europe, and 32% from other regions, with an emphasis on Asia and Australia.

In the past year, Danaher's brand reputation has been impacted by a class-action lawsuit settlement. In April 2026, Danaher agreed to pay $172.5 million to settle a class-action lawsuit accusing the company of misrepresenting demand for its test and vaccine equipment as the impact of the COVID-19 pandemic waned. While agreeing to the settlement, Danaher denied any wrongdoing.

Danaher Corporation's ownership is predominantly institutional, with institutional investors holding approximately 80% of shares. The top 10 institutional investors collectively own 36%. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Individual investors and insiders own about 20% of the company, with Steven M. Rales being the largest individual shareholder, holding 13.16% of the company.